Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Cianni, G.
Right arrow Articles by Del Prato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Cianni, G.
Right arrow Articles by Del Prato, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:982-983, 2005
© 2005 by the American Diabetes Association, Inc.

Letters: Observations

Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women

Graziano Di Cianni, MD, Laura Volpe, MD, Cristina Lencioni, MD, Kyriazoula Chatzianagnostou, MD, Ilaria Cuccuru, MD, Alessandra Ghio, MD, Luca Benzi, MD and Stefano Del Prato, MD

From the Department of Endocrinology and Metabolism, Section of Diabetes, University of Pisa, Pisa, Italy

Address correspondence to Dr. Graziano Di Cianni, Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, Ospedale di Cisanello, Via Paradisa, 2, I-56126 Pisa, Italy. E-mail: dicianni@immr.med.unipi.it

The first 20% of the full text of this article appears below.

The long-acting analog glargine is a new insulin with 24-h persistence. This peculiar peakless action profile accounts for significant risk reduction for nocturnal hypoglycemia and a more stable daily plasma glucose profile (1,2). Only a few reports have described the use of insulin glargine during human pregnancy, so its use is not recommended at present. Animal studies have addressed the safety and efficacy of glargine during pregnancy, showing no direct effect on reproduction and embryo-fetal development (3). Recently, Devlin et al. (4) and Holstein et al. (5) reported the use of insulin glargine in two type 1 diabetic women; both cases were free . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
L. Jovanovic and D. J. Pettitt
Treatment With Insulin and Its Analogs in Pregnancies Complicated by Diabetes
Diabetes Care, July 1, 2007; 30(Supplement_2): S220 - S224.
[Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
A. L. Trujillo
Insulin Analogs and Pregnancy
Diabetes Spectr, April 1, 2007; 20(2): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. M. Woolderink, A. J. van Loon, F. Storms, L. de Heide, and K. Hoogenberg
Use of Insulin Glargine During Pregnancy in Seven Type 1 Diabetic Women
Diabetes Care, October 1, 2005; 28(10): 2594 - 2595.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Dolci, M. Mori, and F. Baccetti
Use of Glargine Insulin Before and During Pregnancy in a Woman With Type 1 Diabetes and Addison's Disease
Diabetes Care, August 1, 2005; 28(8): 2084 - 2085.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.